- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03923530
Pressure Assessment to Improve Outcomes After TAVR: a Registry
At the Malcom Randall Veterans Affairs Medical Center (MRVAMC), invasive cardiac pressures are routinely recorded after transcatheter aortic valve replacement (TAVR) procedures. Our research has disclosed that patients with abnormal hemodynamics (narrow aortic to ventricular end-diastolic pressure difference, indexed to heart rate) suffer from high long-term mortality, compared with patients with normal hemodynamics.This hemodynamic value can be referred to as the aortoventricular index (AVi). Hypertension and diastolic dysfunction are highly co-morbid conditions among these patients. The selective aldosterone receptor antagonist eplerenone (Inspra) is approved for use in the treatment of hypertension. Research also supports that eplerenone may be able to improve diastolic function.
This prospective study is interested in determining 1) the tolerability of eplerenone, and 2) feasibility of administering the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) among subject with abnormal cardiac hemodynamics after TAVR. This study will set the stage for a pilot randomized trial to evaluate eplerenone versus placebo among patients with abnormal hemodynamics after TAVR.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Our research has disclosed that patients who have abnormal invasive cardiac hemodynamics (narrow aortic to ventricular end-diastolic pressure difference, indexed to heart rate) after TAVR suffer from poor long-term survival. This hemodynamic value can be referred to as the aortoventricular index (AVi). In a single center observational study, the 2-year mortality rate for patient with a value ≥0.6 mm Hg/bpm was 25% compared with 36% for patients with a value <0.6 mm Hg/bpm. An abnormal AVi was an independent predictor for poor survival. Hypertension and diastolic dysfunction are 2 highly co-morbid conditions among these patients. Currently, there is lack of appreciation that pressure measurements obtained at the time of TAVR can provide long-term prognostic value. There is also a lack of understanding on how to improve outcomes and quality of life among such patients.
Eplerenone is a selective aldosterone receptor antagonist approved for use for treatment of hypertension. Animal studies have shown that aldosterone receptor antagonists can decrease interstitial myocardial fibrosis. The non-selective aldosterone receptor antagonist, spironolactone 25 mg daily compared with placebo was shown to improve diastolic function, as assessed by echocardiography, among 28 elderly subjects. A meta-analysis of eleven studies in 942 subjects found that aldosterone receptor antagonists improve diastolic function and markers of cardiac fibrosis without significant changes to left ventricular mass or dimensions. In a randomized controlled trial, eplerenone was found to be safely tolerated among asymptomatic patients with moderate to severe aortic stenosis.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32608
- Malcom Randall VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- Enroll 10 subjects with hypertension and abnormal hemodynamics after TAVR.
This is a greater than minimal risk study.
Inclusion criteria:
- TAVR procedure performed at the Malcom Randall VA Medical Center within the last 2 years.
- Intracardiac pressures recorded 5 to 10 minutes after TAVR and AVi < 0.6 mm Hg/bpm.
- History of hypertension, taking anti-hypertensive medications, or recent systolic blood pressure ≥130 mm Hg.
Exclusion criteria:
- Serum potassium >5.5 mEq/L at initiation.
- Concomitant administration of strong CYP3A inhibitor (i.e. ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir).
- Type 2 diabetes with microalbuminuria.
- Serum creatinine >2.0 for men and >1.8 for women.
- Creatinine clearance <50 cc/min.
- Concomitant administration of potassium supplements or potassium-sparing diuretics.
Subjects who are eligible to participate and signed an informed consent will be given eplerenone 50 mg daily. Study drug (eplerenone) will be paid by the North Florida Foundation for Research and Education for the duration of the study.
a. Down-titration or termination of non-essential anti-hypertensive agents is permissible so that eplerenone does not result in hypotension. Essential medications are as follows:
- Angiotensin converting enzyme inhibitors (ACE-inhibitors) or angiotensin receptor blockers, if intolerant to ACE-inhibitors are indicated for treatment left ventricular dysfunction (i.e. left ventricular ejection fraction ≤40%), diabetes, and proteinuric chronic kidney disease.
- Beta-blockers are indicated 3 years after an acute myocardial infarction, unless there is persistent left ventricular dysfunction (i.e. left ventricular ejection fraction ≤40%).
Monitoring.
a. Serum potassium within the last 30 days is required before initiating eplerenone. Repeat blood draw is required within the first week, and one month after the start of treatment with eplerenone.
- Quality of life questionnaire. a. The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) will be administered at baseline and 8 weeks. The KCCQ-12 instrument will be mailed to the subject. Study coordinator will call the subject at 8 weeks to confirm vital status, assess if any adverse reactions from eplerenone, and provide assistance to completing the KCCQ-12, if needed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Eplerenone
Eplerenone 50 mg daily, administered orally for 8 weeks.
|
Eplerenone 50 mg daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Summary Score
Time Frame: Baseline, 8 weeks
|
The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a self-administered health status survey.
The KCCQ-12 has 4 domains (physical limitation, symptom frequency, quality of life, social limitation) and one summary score.
Score are scaled 0-100, where 1 denotes the lowest reportable health status and 100 the highest.
|
Baseline, 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Physical Limitation Score
Time Frame: Baseline, 8 weeks
|
The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a self-administered health status survey.
The KCCQ-12 has 4 domains (physical limitation, symptom frequency, quality of life, social limitation) and one summary score.
Score are scaled 0-100, where 1 denotes the lowest reportable health status and 100 the highest.
|
Baseline, 8 weeks
|
Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Symptom Frequency Score
Time Frame: Baseline, 8 weeks
|
The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a self-administered health status survey.
The KCCQ-12 has 4 domains (physical limitation, symptom frequency, quality of life, social limitation) and one summary score.
Score are scaled 0-100, where 1 denotes the lowest reportable health status and 100 the highest.
|
Baseline, 8 weeks
|
Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Quality of Life Score
Time Frame: Baseline, 8 weeks
|
The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a self-administered health status survey.
The KCCQ-12 has 4 domains (physical limitation, symptom frequency, quality of life, social limitation) and one summary score.
Score are scaled 0-100, where 1 denotes the lowest reportable health status and 100 the highest.
|
Baseline, 8 weeks
|
Kansas City Cardiomyopathy Questionnaire (KCCQ-12)-Social Limitation Score
Time Frame: Baseline, 8 weeks
|
The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a self-administered health status survey.
The KCCQ-12 has 4 domains (physical limitation, symptom frequency, quality of life, social limitation) and one summary score.
Score are scaled 0-100, where 1 denotes the lowest reportable health status and 100 the highest.
|
Baseline, 8 weeks
|
Systolic Blood Pressure
Time Frame: Baseline, 8 weeks
|
Cuff systolic blood pressure
|
Baseline, 8 weeks
|
Diastolic Blood Pressure
Time Frame: Baseline, 8 weeks
|
Cuff diastolic blood pressure
|
Baseline, 8 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Anthony Bavry, MD, University of Florida
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Aortic Valve Disease
- Heart Valve Diseases
- Ventricular Outflow Obstruction
- Aortic Valve Stenosis
- Physiological Effects of Drugs
- Antihypertensive Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Natriuretic Agents
- Diuretics
- Hormone Antagonists
- Mineralocorticoid Receptor Antagonists
- Diuretics, Potassium Sparing
- Eplerenone
Other Study ID Numbers
- 201901097
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaRecruitingImprove Quality of LifeItaly
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Region VästmanlandUnknownHealth Related Quality of Life
-
Ain Shams UniversityCompletedHealth Related Quality of LifeEgypt
-
Institute of Oncology LjubljanaUnknownHealth-related Quality of LifeSlovenia
Clinical Trials on Eplerenone
-
Tufts Medical CenterCompleted
-
Vanderbilt University Medical CenterNational Center for Research Resources (NCRR)Completed
-
Darnitsa Pharmaceutical CompanyACDIMA BiocenterCompletedHealthy Subjects | BioequivalenceJordan
-
Pr. Nicolas GIRERDRecruitingKidney Transplantation for More Than One Year | Patients With a Kidney Transplantation on CyclosporineFrance
-
University of CincinnatiWithdrawnLow Back Pain | Sciatic Radiculopathy | Degenerative Intervertebral DiscsUnited States
-
Subha RamanBallou SkiesCompletedDuchenne Muscular DystrophyUnited States
-
Semmelweis UniversityCompletedChronic Central Serous ChorioretinopathyHungary
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedHealthy VolunteersUnited States
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)WithdrawnHypertensionUnited States